|Bid||21.370 x 1800|
|Ask||21.380 x 4000|
|Day's Range||21.140 - 21.620|
|52 Week Range||18.500 - 32.500|
|PE Ratio (TTM)||26.36|
|Earnings Date||Aug 1, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||33.17|
Exelixis, Inc. (EXEL) announced today that its second quarter 2018 financial results will be released on Wednesday, August 1, 2018 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading.
Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on July 12. Over the last one-month, outflows of investor capital in ETFs holding EXEL totaled $22 million.
Biotech is a notoriously risky business. Many biotechnology products do not produce the desired results consistently, while others fail to gain acceptance in the marketplace. Of course, when a biotech product succeeds, investors can make a lot of money.
After Acceleron’s and Celgene’s (CELG) June 28 announcement of the Phase 3 MEDALIST trial results, Acceleron stock started rising, recording ~42.79% growth on June 29 to close at $48.52. Celgene and Acceleron Pharma conducted the MEDALIST trial to evaluate the safety and efficacy of luspatercept for the treatment of individuals with myelodysplastic syndrome and chronic anemia who are not eligible or are intolerant to erythropoietin-stimulating agents.
This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on July 5. Index (PMI) data, output in the Healthcare sector is rising.
On July 3, Exelixis (EXEL) stock closed at $21.4, a ~15.7% increase from its 52-week low of $18.5 on May 10. On June 26, Exelixis stock rose ~8.0% to close at $21.03 from its previous day’s close of $19.54 on June 25.
– Trial results formed the basis of regulatory filings in the U.S. and European Union for CABOMETYX® for previously treated advanced hepatocellular carcinoma –
In the first quarter of 2018, Exelixis (EXEL) generated $71.8 million from operating activities compared to $68.85 million in Q1 2017. The increase in operating cash flow was primarily attributable to the increase in Exelixis’s net income, offset by an increase in trade and other receivables of $10.75 million in Q1 2018 compared to a decrease of $6.54 million in Q1 2017. It was also attributable to unbilled collaboration revenue of $38 million in Q1 2018 and a decrease in deferred revenues of $2.65 million compared to an increase of $35.14 million in Q1 2017.
Exelixis (EXEL) has collaboration agreements with Ipsen, Takeda, and Genentech. Revenues from Ipsen increased from $4.5 million in Q1 2017 to $53.81 million in Q1 2018. Under Exelixis’s collaboration with Takeda for cabozantinib, revenues were $2.92 million in Q1 2018 compared to $2.68 million in Q1 2017. Revenues from Genentech on the US commercialization of Cotellic were $1.34 million in Q1 2018 compared to $2.29 million in Q1 2017.
Exelixis (EXEL) generated total revenues of $212.34 million in Q1 2018 compared to $80.88 million in Q1 2017. It generates revenues from product sales and collaborations. Exelixis’s collaboration revenues also registered strong growth in the quarter, rising from $12 million in Q1 2017 to $78 million in Q1 2018.
Exelixis (EXEL) is a biotechnology company focused on discovering, developing, and commercializing drugs to treat cancer. Two of them—Cabometyx and Cometriq—are derived from cabozantinib, a multiple tyrosine kinase inhibitor. Exelixis’s third commercial product, Cotellic, is a MEK inhibitor approved as part of a combination therapy for advanced melanoma and is marketed in collaboration with Genentech.
Exelixis, Inc. (EXEL) today announced that it will be added to Standard & Poor’s (S&P) MidCap 400 index, effective prior to the open of trading on Monday, July 2. The company will be classified under S&P’s Global Industry Classification Standard (GICS) Biotechnology Sub-Industry index. “S&P is a highly respected organization in the investment and financial communities, so Exelixis’ addition to the S&P MidCap 400 is an important milestone as we continue on our growth trajectory,” said Michael M. Morrissey, Ph.D., President and Chief Executive Officer of Exelixis.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 25) Quest Diagnostics Inc (NYSE: DGX )(Barclays upgraded shares ...
NEW YORK, NY / ACESSWIRE / June 26, 2018 / U.S. equities plunged on Monday, as indexes posted their biggest one-day decline in week, as fresh threats from President Trump added to the uncertainties of ...
NEW YORK, June 25, 2018 /PRNewswire/ -- S&P MidCap 400 constituent Copart Inc. (CPRT) will replace Dr Pepper Snapple Group Inc. (DPS) in the S&P 500, and Exelixis Inc. (EXEL) will replace Copart in the S&P MidCap 400 effective prior to the open of trading on Monday, July 2. Dr Pepper Snapple Group, which is merging with privately held Keurig Green Mountain Inc., is changing its name to Keurig Dr Pepper Inc. and its ticker symbol (NYSE:KDP) in a transaction expected to be completed soon. The newly combined company will no longer be eligible for inclusion in the S&P 500 as its Investable Weight Factor (IWF), which measures the percentage of free float available to the public, is expected to fall well below the 50% eligibility threshold needed for continued inclusion in the index.
NEW YORK, NY / ACCESSWIRE / June 21, 2018 / U.S. markets were mixed Wednesday as global trade concerns continue to be a focus. The Nasdaq and S&P 500 Index posted gains driven by deal making activities ...
Attractive stocks have exceptional fundamentals. In the case of Exelixis Inc (NASDAQ:EXEL), there’s is a financially-healthy company with a great history and an optimistic growth outlook. Below is a briefRead More...
Pre-market today, WallStEquities.com reviews these four Biotechnology stocks: Endocyte Inc. (NASDAQ:ECYT), Epizyme Inc. (EPZM), Esperion Therapeutics Inc. (ESPR), and Exelixis Inc. (EXEL).All you have to do is sign up today for this free limited time offer by clicking the link below. West Lafayette, Indiana headquartered Endocyte Inc.'s stock finished Wednesday's session 3.46% higher at $14.64.
It's that time again! "Mad Money" host Jim Cramer rang the lightning round bell, which means he gave his take on callers' favorite stocks at rapid speed. General Electric Company GE : "[CEO] John Flannery is doing his best with one of the worst hands that anyone's ever been given. The company just was not forthcoming.' Now that they're being forthcoming, all I can say is listen to [J.P. Morgan JPM analyst] Steve Tusa.
As an investor, I look for investments which does not compromise one fundamental factor for another. By this I mean, I look at stocks holistically, from their financial health toRead More...
NEW YORK, June 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Rayonier ...